InsiderTrades

Form 4 for VIR Vir Biotechnology, Inc.

Accepted 2026-08-12 14:30:46 ET · period of report 2026-08-11 · accession 0001628280-26-056108 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
2026-08-12 14:30 2026-08-11 VIR MORE ROBERT J Dir J - Other $0.00 -8,000 40.7K -16% $0
I 2026-08-12 14:30 2026-08-11 VIR MORE ROBERT J Dir J - Other $0.00 +8,000 517.9K +2% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-08-11 J D 8,000 $0.00 40,656 D — — (F1) Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred by the Reporting Person for no consideration to APNG 1 in connection with the vesting of restricted stock unit (RSU) awards.
2 Common Common Stock 2026-08-11 J A 8,000 $0.00 517,917 I See footnote — — (F1) Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred by the Reporting Person for no consideration to APNG 1 in connection with the vesting of restricted stock unit (RSU) awards. (F2) The shares are held by APNG 1. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG I. As such, the Reporting Person may be deemed to beneficially own the shares held by APNG 1; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.